Navigation Links
PharMEDium Registers with FDA as an 'Outsourcing Facility' Under New Drug Quality and Security Act
Date:12/9/2013

LAKE FOREST, Ill., Dec. 9, 2013 /PRNewswire/ -- PharMEDium announced today that it is registered with the U.S. Food and Drug Administration (FDA) as a 503B large-scale sterile compounding "outsourcing facility" under the recently enacted Drug Quality and Security Act (DQSA).

The law, signed by the President on November 27, 2013, calls for large-scale entities engaged in non-prescription anticipatory compounding to voluntarily register with the FDA under the newly created section 503B of the federal Food, Drug, and Cosmetic (FDC) Act.

"Our customers can continue to expect a high level of disclosure and transparency based on this new official outsourcing facility category and clarifying rules that govern it," said David Jonas, Chairman and CEO of PharMEDium Healthcare Corp. "Going forward, there will be more consistent regulations and consistent oversight, which should raise the level of confidence among hospital leaders, providers and their patients."

FDA urges providers to purchase from registered compounders

During a media briefing last week, FDA Commissioner Margaret Hamburg, MD, said: "Helping to protect Americans from unsafe drugs is among the FDA's highest priorities and is part of our core mission." She explained that the DQSA "represents a step forward by creating a new pathway in which a compounder can register with FDA as an outsourcing facility."

Dr. Hamburg said that the section of the new law pertaining to compounders will give healthcare providers and health networks greater safeguards as related to medication safety if they purchase compounded products from registered outsourcing facilities.

"If compounders register with FDA as outsourcers, hospitals and other healthcare providers will be able to provide their patients with drugs that were compounded in facilities that are subject to increased FDA oversight, including inspections on a risk-based schedule, and federal requirements for current good manufacturing process, among others," Dr. Hamburg said.

She added: "With that in mind, we'll be encouraging healthcare providers and health networks to consider strongly purchasing compounded products from FDA-registered and regulated facilities. This will be a critical step they can take to better ensure the health and safety of their patients."

Dr. Hamburg said that FDA will be posting a list of registered compounders on its website to serve as a resource for healthcare providers, facilities and networks.

A transcript of the full media briefing is available at: www.fda.gov/NewsEvents/Newsroom/MediaTranscripts/ucm334695.htm.

Clearer authority, stronger oversight for FDA

"PharMEDium has long advocated for clearer FDA authority and stronger oversight and believes that when the law is implemented swiftly and fully, the DQSA will help prevent another national tragedy like last year's devastating fungal meningitis outbreak," said Rich Kruzynski, President of PharMEDium. The company has been voluntarily registered with the FDA since the company's inception — more than a decade before it was requested by this much-needed new law.

The 503B registration obligates outsourcing facilities to comply with FDA oversight, manufacturing-like safety standards and routine inspection by the Agency. If an entity declines to register with the FDA, then it is not an "outsourcing facility," and its operation will be regulated under a different section of the FDC Act, 503A. Entities that do not elect to become 503B registrants and are engaged in large-scale anticipatory compounding without prescriptions are likely in violation of one or more provisions of the FDC Act if they are not inspected to the higher level of the FDA.

PharMEDium's registration as an outsourcing facility under the DQSA is based on draft guidance released by the FDA and listed in the Federal Register on December 4, 2013. Apart from the registration instructions, the draft guidance includes new drug labeling and drug event reporting regulations, and it also requires outsourcing facilities to submit a detailed report to the FDA identifying all drugs compounded by the facility during the previous six-month period. PharMEDium is actively engaged in complying with all draft guidelines.

Who we are: 

PharMEDium is the nation's leading provider of hospital pharmacy-outsourced, sterile admixture services with centers in four states and thousands of acute care hospital customers nationwide. Our qualified personnel and state-of-the-art centers are registered with the FDA, licensed by states as compounding pharmacies, and governed by our own rigorous quality standards. We begin the compounding process with FDA-approved sterile drugs, diluent and containers from FDA-approved manufacturers. It is our mission to be the preeminent provider of choice for hospital customers and to attain the highest degree of integrity in the compounding of sterile preparations.


'/>"/>
SOURCE PharMEDium
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo
2. PharMEDium Encourages Swift Action to Strengthen Federal Oversight of Advanced Sterile Compounding
3. PharMEDium Supports Draft Legislation, Efforts to Strengthen Oversight of the Compounding Industry
4. PharMEDium Applauds Passage of Legislation to Strengthen Oversight of the Compounding Industry
5. Absorption Systems Registers with FDA as a Generic Drug Facility under GDUFA
6. Synteract Sponsoring and Presenting at Outsourcing in Clinical Trials Southeast Conference
7. Millstone Medical Outsourcing Hires New Vice President Quality
8. Emerging Trends in Medical Device Outsourcing and Contract Manufacturing
9. This Week: UBM Canon Presents an Online Event and Conference Dedicated to Emerging Trends in Medical Device Outsourcing/Contract Manufacturing
10. Genpact and AstraZeneca Win Outsourcing Center and SSON Awards
11. New White Paper, "Five Biggest Myths about Medical Products Outsourcing," Finds OEMs Concerns are Often Unfounded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... Switzerland , April 27, 2016 ... AG announced the launch of a Phase 2 clinical ... residual hearing in patients undergoing cochlear implantation (CI) surgery. ... recruiting patients in Germany and ... into the middle ear at the time of surgery. ...
(Date:4/26/2016)... 26, 2016 Hill-Rom Holdings, Inc. (NYSE: ... at the Deutsche Bank 41 st Annual Health Care ... You are invited to listen to the live ... access it directly at http://edge.media-server.com/m/p/mr4uxgas . A recorded replay ... of the live event and accessible at the links above ...
(Date:4/26/2016)... , April 27, 2016 Research ... "Global Molecular Diagnostics Market 2016-2020" report to their ... , ,The global molecular diagnostics market is projected to ... 2016-2020. Molecular diagnostics is a technique that ... the molecular level to detect changes in biochemical pathways. ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... In an article published April 16th on the ... and lip injections, which she underwent in order to feel more at home at ... Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic surgeons ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic ... the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for brain ... mood optimization products to the store is just one more way Shamangelic Healing ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce is on ... security. Most importantly, employees are the single most important asset in creating value ... unhappy? , Just under half of American workers are emotionally checked out with ...
(Date:4/29/2016)... ... , ... Conditions were ideal for Global Lyme Alliance’s (GLA) 2nd annual “Bite ... a light breeze and temperatures in the 60s. Over 400 runners, walkers and volunteers ... and 1-mile walk were held to increase awareness about Lyme disease and to ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine physician ... one of their physicians has been invited to be a featured speaker at the ... Review conference on April 30, 2016. , Dr. R. Scott McPherson, a physical ...
Breaking Medicine News(10 mins):